[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615952":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":73,"collaborators":20,"id":75,"slug":20,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":20,"eligibilityCriteria":79,"healthyVolunteers":76,"sex":80,"minAge":81,"maxAge":20,"enrollmentInfo":82,"targetDuration":20,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"SMED Clinical Research","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"single-cohort","EXPERIMENTAL","Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.",[13],"Drug: Abiraterone 250 mg with food + prednisone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Abiraterone 250 mg with food + prednisone","Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases",[9],null,[22,40,56],{"facility":23,"status":24,"city":25,"state":20,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Hospital Carlos A Durand","RECRUITING","Buenos Aires","5044","Argentina",{"type":29,"coordinates":30},"Point",[31,32],-58.37723,-34.61315,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":20,"email":39},"Diego Barreiro, MD","CONTACT","+5491149940794","diegomartinbarreiro@hotmail.com",{"facility":41,"status":42,"city":43,"state":20,"zip":20,"country":44,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Hospital San José","NOT_YET_RECRUITING","Hermosillo","Spain",{"type":29,"coordinates":46},[47,48],-5.47372,40.3349,{"lat":48,"lon":47},[51,55],{"name":52,"role":37,"phone":53,"phoneExt":20,"email":54},"Danny Mena, MD","+527291081110","dmena@theranuks.com",{"name":20,"role":37,"phone":20,"phoneExt":20,"email":54},{"facility":57,"status":24,"city":58,"state":20,"zip":59,"country":44,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Instituto Oriente Boliviano","Santa Cruz de la Sierra","10260",{"type":29,"coordinates":61},[62,63],-5.84561,39.33635,{"lat":63,"lon":62},[66,70],{"name":67,"role":37,"phone":68,"phoneExt":20,"email":69},"Lucía Ritcher Lucia Ritcher, MD","+5491149940783","smeclinicalresearch@gmail.com",{"name":71,"role":72,"phone":20,"phoneExt":20,"email":20},"Lucia Ritcher","PRINCIPAL_INVESTIGATOR",{"type":74,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100615952",false,"NCT07299292","Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed prostate adenocarcinoma.\n* Treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia).\n* Indicated for hormonal intensification (high\u002Fvery high risk candidates for RT, or mHSPC for doublet\u002Ftriplet).\n* No prior ADT.\n* ECOG 0-2; adequate hepatic\u002Frenal function; K+ ≥3.5 mmol\u002FL; controlled BP.\n\nExclusion Criteria:\n\n* Hypersensitivity to ABI\u002Fprednisone; moderate-severe hepatic impairment; uncontrolled hypertension; refractory hypokalemia.\n* Concurrent therapy with strongly contraindicated\u002Finducing drugs affecting ABI levels without possibility of adjustment.","MALE","18 Years",{"count":83,"type":84},60,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","Hypothesis\n\nThe use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.",[90],"Prostate Cancer (Diagnosis)",[92,93,94,95],"prostate cancer","castration","abiraterone","hormonal intensification","2025-12-09",{"date":98,"type":99},"2025-12-23","ACTUAL",{"date":101,"type":99},"2025-12-01",{"date":103,"type":84},"2027-03-30",{"name":5,"class":6},3]